Navigation Links
Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
Date:6/22/2013

e global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2012, Boehringer Ingelheim achieved net sales of about $19.1 billion (14.7 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 22.5 percent of its net sales. For more information please visit www.us.boehringer-ingelheim.com.

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, IN, Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we work to meet the diverse needs of people with diabetes through research and collaboration, a broad and growing product portfolio and a continued commitment to providing real solutions – from medicines to support programs and more – to make lives better.

For more information, visit www.lillydiabetes.com.

P-LLY
DIA568105PR

This press release contains forward-looking statements about empagliflozin* for the treatment of type 2 diabetes. It reflects Lilly's current beliefs; however, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization. There is no guarantee that future study results and patient exp
'/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... -- Investor-Edge has initiated coverage on the ... ), NPS Pharmaceuticals Inc. (NASDAQ: NPSP ), ... Inc. (NASDAQ: MNTA ), and Catalyst Pharmaceutical ... companies can be accessed at: http://investor-edge.com/register . ... ended on a mixed note as the Dow Jones ...
(Date:10/17/2014)... -- Ameritox SM , the nation,s leader in medication monitoring ... , M.D., as Chief Medical Officer. In this role, ... for healthcare providers, patients and managed care plans.   ... variety of healthcare companies that have provided him with ... health sides of Ameritox,s business. He most recently served ...
(Date:10/17/2014)... ANGELES , Oct. 17, 2014 CytRx ... and development company specializing in oncology, announced that data ... aldoxorubicin for the treatment of first-line soft tissue sarcoma ... at the 2014 Connective Tissue Oncology Society (CTOS) Annual ... Berlin , Germany. Due to the longer ...
Breaking Medicine Technology:Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5Ameritox Appoints New Chief Medical Officer 2CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 2CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 3CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 4CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 5CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 6
... Inc. (OTC Bulletin Board: MCLN ), the leading ... and disposal of medical waste and the destruction of ... the 2010 second quarter for the period ended June 30, ... MedClean has addressed its capital requirements ...
... Group, Inc., (EHG), parent company of DentalXChange, a ... solutions for patients, payers and providers in the ... has selected DentalXChange as its latest Endorsed Program. ... members to receive an immediate savings on DentalXChange,s ...
Cached Medicine Technology:MedClean Technologies Announces Second Quarter Results 2MedClean Technologies Announces Second Quarter Results 3MedClean Technologies Announces Second Quarter Results 4MedClean Technologies Announces Second Quarter Results 5DentalXChange Endorsed by California Dental Association 2DentalXChange Endorsed by California Dental Association 3
(Date:10/20/2014)... 20, 2014 Succeed is proud to announce ... who participated in the Every Body Walk! campaign ... awareness project that encourages workers to be more active outside ... Program, which concluded at the end of September, was a ... and metro areas. Participating companies gave their staff pedometers ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Unveiled at the ... Strategic Direction Scorecard conservatively estimates member hospital ROI on membership ... on dues, The Center provides $12.50 in value to member ... (Member Value – Member Dues)/Member Dues. , “This is ... this number and we think the methodology is really sound,” ...
(Date:10/20/2014)... Spring, Maryland, USA (PRWEB) October 20, 2014 ... or to track interventions? Here comes a wonderful app ... mobile app development company helped its client ... Intervention more efficiently. The app is designed for iOS ... and iPod touch. This app is optimized for iPhone ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 Dr. Babatunde ... Fund, welcomes news of a ceasefire agreement that is ... than 200 girls who were kidnapped from the north-eastern ... languished in captivity long enough, and it is high ... communities," stated Dr. Osotimehin. , "We owe it to ...
(Date:10/19/2014)... October 20, 2014 Recently, Fancyflyingfox.com, an ... occasion clothes, has announced its latest designs of 2014 ... all the new elegant outfits are offered with big ... an order before October 30 can enjoy this special ... great marketing strategies, it has become one of the ...
Breaking Medicine News(10 mins):Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2
... no longer have to worry about the doctor's needle, for ... treatment works just as well as injections. ... University of Nottingham showed that kids children given oral treatment ... in hospital and were able to go home sooner than ...
... obesity and heart disease, chronic illnesses in wealthy nations, ... countries by 2015. ,These diseases will replace ... tuberculosis. ,In its report the Bank emphasized the ... impending burden such a situation would impose on the ...
... Internal Medicine ,a plate and cereal bowl with markers ... with diabetes lose weight and decrease their use ... the proportion of U.S. adults who were obese increased ... information in the article. Most cases of type 2 ...
... According to a study published in the Journal of ... stage metastatic breast cancers is increasing, but this ... , Deirdre Cronin-Fenton, Ph.D., of Aarhus University ... Institute in Bethesda, Md., found that the increase in ...
... and many other dangerous ingredients have been found in ... reported Wednesday. ,A nationwide investigation by ... milk powder, rice, flour, meat, biscuits, seafood, soy sauce ... 23,000 tainted or sub-standard foods were found and 180 ...
... are at an increased risk of jaw or facial ... cancer-related bone lesions, elevated levels of calcium in ... recent studies have found an association between the use ... facial bones, a condition in which poor blood supply ...
Cached Medicine News:Health News:Oral Treatment as Effective as Injections in Treating Kids With Pneumonia 2Health News:Non Communicable Diseases to Be the Cause of Deaths in Poor Countries by 2115-World Bank 2Health News:Weight Control for Obese Diabetics 2Health News:China Uncovers Thousands of Dangerous Foods 2Health News:Bisphosphonate Increases the Risk of Jaw Bone Deterioration 2
... Dye Fluorometer utilizes unique microprocessor-controlled filter wheels ... detection optics. The filter wheels can be ... types of applications. With this fluorometer, you ... one or two wavelengths. The C&L Dye ...
The VICTOR² D fluorometer is suitable for clinical assays based on fluorescence or time-resolved fluorescence from a wide variety of plates....
... to end transcription services. Zodiac offers ... be either submitted over the phone ... call 24 hours a day, 7 ... be recorded on a digital handheld ...
Liquid, ready-to-use, bar-coded Olympus reagents are convenient, economical easy-to-use and reliable. This is one of 122 tests standardized for use on the Olympus AU400e, AU640e, AU2700, and AU5400 C...
Medicine Products: